Welcome to the Oncology Brothers podcast! In this episode, we dived into the latest advancements in multiple myeloma treatment, focusing on the practice changing ENDURANCE trial. Joined by esteemed guests Dr. Shaji Kumar and Dr. Vincent Rajkumar from Mayo Clinic, they discussed the new time limited approach being the standard of care for maintenance therapy in standard-risk multiple myeloma patients.

Key topics include:

Overview of the ENDURANCE trial and its implications for clinical practice
The significance of limiting lenalidomide maintenance therapy to two years
The role of minimal residual disease (MRD) testing in treatment decisions
Insights on high-risk cytogenetics and future directions for therapy

This episode is a must-listen for community oncologists and anyone interested in the evolving landscape of cancer treatment. Tune in to learn how these findings can impact patient care and improve outcomes!

Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

Don't forget to like, subscribe, and check out our other episodes for more discussions on treatment algorithms, conference highlights, and challenging cases in oncology.

#MultipleMyeloma, #ENDURANCE, #Lenalidomide, #MRD, #OncologyBrothers

ENDURANCE Trial - Time-limited Lenalidomide Maintenance for Standard Risk Myeloma

Oncology Brothers: Practice-Changing Cancer Discussions

ENDURANCE Trial - Time-limited Lenalidomide Maintenance for Standard Risk Myeloma